A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)
Phase of Trial: Phase I/II
Latest Information Update: 12 Jun 2019
Price : $35 *
At a glance
- Drugs Dubermatinib (Primary) ; Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Tolero Pharmaceuticals
- 12 Jun 2019 According to a Tolero Pharmaceuticals media release, the first patient has been dosed in this study.
- 12 Mar 2019 Status changed from not yet recruiting to recruiting.
- 29 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 1 Nov 2018.